Athenex, Inc. (ATNX) Misses Q2 EPS by 13c

Go back to Athenex, Inc. (ATNX) Misses Q2 EPS by 13c

Athenex Provides Second Quarter 2022 Financial Results and Business Update

July 28, 2022 7:00 AM EDT

Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respectivelyMaintains full-year 2022 product revenue guidance range of 20-25% growth year-over-year... More